BIOCRYST PHARMACEUTICALS INC (BCRX)       10.58  -0.2 (-1.86%)

10.58  -0.2 (-1.86%)

US09058V1035 - Common Stock - After market: 10.74 +0.16 (+1.51%)

News Image
2 days ago - BioCryst Pharmaceuticals, Inc.

BioCryst Begins Enrollment in Pivotal APeX-P Trial Evaluating ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema

RESEARCH TRIANGLE PARK, N.C., Jan. 26, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the enrollment of the first...

News Image
5 days ago - BioCryst Pharmaceuticals, Inc.

BioCryst Selects Swixx BioPharma as Commercial Partner for ORLADEYO® (berotralstat) in Central and Eastern Europe

RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the company has entered...

News Image
19 days ago - Seeking Alpha

BCRX stock drops as sales for hereditary angioedema therapy lag forecasts (NASDAQ:BCRX)

BioCryst Pharmaceuticals (BCRX) fell ~12% on Monday after announcing lower-than-expected sales for the company's hereditary angioedema therapy Orladeyo. Read the full story here.

News Image
19 days ago - BioCryst Pharmaceuticals, Inc.

BioCryst Announces Preliminary Full Year 2022 ORLADEYO® (berotralstat) Net Revenue and Provides Full Year 2023 ORLADEYO Net Revenue Guidance

—ORLADEYO preliminary 2022 full year net revenue of $251.6 million (+105 percent y-o-y)— —ORLADEYO net revenue expected to be no less than $320 million in...

News Image
19 days ago - BioCryst Pharmaceuticals, Inc.

BioCryst Reports Initial Clinical Data with Oral Factor D Inhibitor BCX10013 Supporting Development as a Once-daily Treatment for Complement-mediated Diseases

—Company also expanding its discovery platform in complement-mediated diseases, including potent, selective, oral molecules targeting C2— RESEARCH...

News Image
23 days ago - BioCryst Pharmaceuticals, Inc.

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Jan. 05, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation...

News Image
24 days ago - BioCryst Pharmaceuticals, Inc.

BioCryst to Present at 41st Annual J.P. Morgan Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., Jan. 04, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will...

News Image
a month ago - InvestorPlace

TSLA Stock Price Prediction: What to Know as Analysts Slash Tesla Price Targets

Tesla (TSLA) stock is in the news as price predictions continue to be a hot topic among traders after Elon Musk's Twitter purchase.

News Image
a month ago - InvestorPlace

Why Is Getaround (GETR) Stock Up 6% Today?

Getaround (GETR) stock is on the move Thursday with heavy trading despite a lack of recent news concerning the car-sharing service.

News Image
a month ago - InvestorPlace

BCRX Stock Sinks as BioCryst Discontinues Drug Development

BioCryst Pharmaceuticals (BCRX) stock is falling on Thursday after revealing it's no longer developing BCX9930 for competitive reasons.

News Image
a month ago - Seeking Alpha

BCRX stock falls on plans to drop oral Factor D inhibitor (NASDAQ:BCRX)

BioCryst Pharmaceuticals (BCRX) shed ~8% pre-market Thursday on a decision to discontinue BCX9930, an oral inhibitor of Factor D at complement-mediated diseases. Read the full story here.

News Image
a month ago - BioCryst Pharmaceuticals, Inc.

BioCryst Discontinues Development of BCX9930 and Shifts Focus to Potential Once-daily, Oral Factor D Inhibitor, BCX10013

RESEARCH TRIANGLE PARK, N.C., Dec. 15, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that, based on new...

News Image
2 months ago - Seeking Alpha

Bad flu season turned even worse around Thanksgiving - CDC

A flu season that began early and severe in October has become even worse, with the CDC reporting an uptick in cases the week of Thanksgiving.media briefing, CDC...

News Image
2 months ago - BioCryst Pharmaceuticals, Inc.

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Dec. 05, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation...

News Image
2 months ago - BioCryst Pharmaceuticals, Inc.

BioCryst to Present at JMP Securities Hematology & Oncology Summit

RESEARCH TRIANGLE PARK, N.C., Dec. 05, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will...

News Image
2 months ago - BioCryst Pharmaceuticals, Inc.

BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Israeli Ministry of Health

RESEARCH TRIANGLE PARK, N.C., Nov. 28, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Israeli Ministry...

News Image
3 months ago - Investor's Business Daily

BioCryst Pharmaceuticals Stock Sees RS Rating Rise To 84

The Relative Strength (RS) Rating for BioCryst Pharmaceuticals stock climbed into a new percentile Friday, with a rise from 64 to 84.

News Image
3 months ago - BioCryst Pharmaceuticals, Inc.

BioCryst Presents Real-World Data Showing Rapid and Sustained HAE Attack Rate Reduction After Beginning ORLADEYO® (berotralstat), Regardless of Prior Prophylactic Therapy

RESEARCH TRIANGLE PARK, N.C., Nov. 10, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world data...

News Image
3 months ago - BioCryst Pharmaceuticals, Inc.

BioCryst to Present at Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., Nov. 09, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will...

News Image
3 months ago - BioCryst Pharmaceuticals, Inc.

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Nov. 04, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation...

News Image
3 months ago - The Motley Fool

BioCryst Pharmaceuticals (BCRX) Q3 2022 Earnings Call Transcript

BCRX earnings call for the period ending September 30, 2022.